Xtant Medical Holdings
Open
$0.44
Prev. Close
$0.44
High
$0.44
Low
$0.44
Market Snapshot
$63.03M
34.5
-0.12
$117.27M
151
Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The company is headquartered in Belgrade Montana, Montana and currently employs 151 full-time employees. The company went IPO on 2010-06-30. The firm's products serve the specialized needs of orthopedic and neurological surgeons, as well as trauma, foot and ankle, sports medicine, wound care surgeons including orthobiologics for the promotion of bone healing, amniotic tissue and collagen for both surgical repair and chronic wound care, implants and instrumentation for the treatment of spinal disease. Its orthobiologics products include OsteoSponge, OsteoSelect DBM Putty, OsteoSelect PLUS DBM Putty, 3Demin, OsteoFactor Pro, OsteoVive Plus, and nanOss. Its spinal implant product categories include cervical, thoracolumbar, sacroiliac joint, and interbody. The firm has exclusive United States distribution rights to Dilon's HEMOBLAST Bellows.
Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The company is headquartered in Belgrade Montana, Montana and currently employs 151 full-time employees. The company went IPO on 2010-06-30. The firm's products serve the specialized needs of orthopedic and neurological surgeons, as well as trauma, foot and ankle, sports medicine, wound care surgeons including orthobiologics for the promotion of bone healing, amniotic tissue and collagen for both surgical repair and chronic wound care, implants and instrumentation for the treatment of spinal disease. Its orthobiologics products include OsteoSponge, OsteoSelect DBM Putty, OsteoSelect PLUS DBM Putty, 3Demin, OsteoFactor Pro, OsteoVive Plus, and nanOss. Its spinal implant product categories include cervical, thoracolumbar, sacroiliac joint, and interbody. The firm has exclusive United States distribution rights to Dilon's HEMOBLAST Bellows.
Recently from Cashu
Xtant Medical Partners with Dilon Technologies for HEMOBLAST® Bellows Distribution Rights
Xtant Medical Holdings, Inc. announces a pivotal development in its strategic initiatives by entering into an exclusive distribution agreement with Dilon Technologies, Inc. for the HEMOBLAST® Bellows…
Xtant Medical Transforms Focus Towards Growth After Strategic Divestitures and Capital Influx
Xtant Medical Focuses on Growth Amid Strategic Divestitures Xtant Medical Holdings, Inc. is making significant strides in its strategic transformation following the recent receipt of $10.7 million fro…
Xtant Medical Focuses on Biologics After Successful $10.7 Million Asset Sale
Xtant Medical Strengthens Focus on Biologics Following Key Asset Sale Xtant Medical Holdings, Inc., a renowned player in the medical technology sector, enhances its strategic focus following the recei…
Xtant Medical Gains $10.7 Million to Focus on Biologics After Asset Sale to Companion Spine
Xtant Medical Secures $10.7 Million from Companion Spine, Enhancing Focus on Biologics Business Xtant Medical Holdings, Inc. announces a significant financial boost with the receipt of $10.7 million f…